# Akili Interactive

于2024年6月获得FDA授权批准EndeavorOTC，这是FDA首次批准通过电子游戏形式提供的成人ADHD数字治疗，并于2026年6月与盐野义制药合作在日本推出ENDEAVORRIDE，成为该市场首款用于儿童ADHD辅助治疗的应用程序。

Source: https://cn.bioecon.ru/companies/akili-interactive/
Updated: 2026-07-20

- 国家: United States
- 代码: AKLI

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 截至2024年3月31日的三个月为$383,000 (2024-03-31) | https://www.sec.gov/Archives/edgar/data/1850266/0000950170-24-059580.txt |
| 营收 | 2023全年为$1.7 million (2023-12-31) | https://www.businesswire.com/news/home/20240229955450/en/Akili-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update |
| 监管批准 | EndeavorOTC（AKL-T01）作为成人 ADHD 非处方治疗获 FDA 许可 (2024-06-18) | https://www.businesswire.com/news/home/20240618578815/en/Akili-Announces-FDA-Authorization-of-EndeavorOTC-the-First-FDA-Clearance-of-a-Digital-Treatment-for-Adults-with-ADHD-Through-a-Video-Game |
| 监管批准 | EndeavorRx（AKL-T01）作为儿童 ADHD 处方治疗获 FDA 许可 (2020-06-15) | https://www.akiliinteractive.com/news-collection/akili-announces-endeavortm-attention-treatment-is-now-available-for-children-with-attention-deficit-hyperactivity-disorder-adhd-al3pw |
| 总部 | 美国马萨诸塞州波士顿 (2022-07-31) | https://content.edgar-online.com/ExternalLink/EDGAR/0001193125-22-227561.html?dest=d379749dex31_htm&hash=783102cbc29d0f012cdb0dcb10dbb360d408d0e9382fa96b4109bc83832af706 |

独立来源: businesswire.com, content.edgar-online.com, sec.gov

## 技术

- [数字疗法](https://cn.bioecon.ru/technology/digital-therapeutics/)